AIM: This work represents the first reported investigation on the effects of magnetic nanoparticles (MNPs) in nonhuman primates. Biodistribution, biocompatibility and nanotoxicity of maghemite nanoparticles stabilized with dimercaptosuccinic acid (DMSA) were accessed. MATERIALS & METHODS: A control animal was used and three other animals were intravenously injected with DMSA-MNPs and euthanized 12 h, 30 and 90 days following administration. Extracted organs were processed by histological techniques. An additional animal was used to collect blood samples to complementarily assess biocompatibility 12 h, 7, 15, 30, 60 and 90 days after DMSA-MNP injection. RESULTS: DMSA-MNPs were preferentially addressed to the lungs, liver and kidneys. Hematological and serum biochemical results corroborated histological findings, supporting DMSA-MNP biocompatibility while preserving both hepatic and renal normal activity. CONCLUSION: DMSA-MNPs were preferentially distributed to the lung, liver and kidneys. Furthermore, DMSA-MNPs were considered biocompatible, supporting their application as a promising nanomaterial platform for future biomedical use.
AIM: This work represents the first reported investigation on the effects of magnetic nanoparticles (MNPs) in nonhuman primates. Biodistribution, biocompatibility and nanotoxicity of maghemite nanoparticles stabilized with dimercaptosuccinic acid (DMSA) were accessed. MATERIALS & METHODS: A control animal was used and three other animals were intravenously injected with DMSA-MNPs and euthanized 12 h, 30 and 90 days following administration. Extracted organs were processed by histological techniques. An additional animal was used to collect blood samples to complementarily assess biocompatibility 12 h, 7, 15, 30, 60 and 90 days after DMSA-MNP injection. RESULTS:DMSA-MNPs were preferentially addressed to the lungs, liver and kidneys. Hematological and serum biochemical results corroborated histological findings, supporting DMSA-MNP biocompatibility while preserving both hepatic and renal normal activity. CONCLUSION:DMSA-MNPs were preferentially distributed to the lung, liver and kidneys. Furthermore, DMSA-MNPs were considered biocompatible, supporting their application as a promising nanomaterial platform for future biomedical use.
Authors: Hector Katifelis; Iuliia Mukha; Penelope Bouziotis; Nadiia Vityuk; Charalampos Tsoukalas; Andreas C Lazaris; Anna Lyberopoulou; George E Theodoropoulos; Efstathios P Efstathopoulos; Maria Gazouli Journal: Int J Nanomedicine Date: 2020-08-12
Authors: Marcella Lemos Brettas Carneiro; Raphael C A Peixoto; Graziela A Joanitti; Ricardo G S Oliveira; Luis A M Telles; Ana L Miranda-Vilela; Anamélia L Bocca; Leonora M S Vianna; Izabel C R da Silva; Aparecido R de Souza; Zulmira G M Lacava; Sônia N Báo Journal: J Nanobiotechnology Date: 2013-02-16 Impact factor: 10.435
Authors: Mariana Campos da Paz; Maria de Fátima M Almeida Santos; Camila M B Santos; Sebastião W da Silva; Lincoln Bernardo de Souza; Emília C D Lima; Renata C Silva; Carolina M Lucci; Paulo César Morais; Ricardo B Azevedo; Zulmira G M Lacava Journal: Int J Nanomedicine Date: 2012-10-04
Authors: Charalampos Tsoukalas; Dimitrios Psimadas; George A Kastis; Vassilis Koutoulidis; Adrian L Harris; Maria Paravatou-Petsotas; Maria Karageorgou; Lars R Furenlid; Lia A Moulopoulos; Dimosthenis Stamopoulos; Penelope Bouziotis Journal: Front Chem Date: 2018-06-20 Impact factor: 5.221